Rafael Amado, Allogene head of R&D

Af­ter call­ing a lengthy time out on the de­vel­op­ment field, Al­lo­gene fi­nal­ly kicks off a land­mark PhII piv­otal

When I talked with Al­lo­gene $AL­LO CEO David Chang back in the spring of 2020 about some new da­ta for their off-the-shelf CAR-T, he ea­ger­ly high­light­ed plans for a Phase II piv­otal tri­al, a po­ten­tial­ly ground­break­ing de­vel­op­ment for pa­tients who cur­rent­ly have lim­it­ed ac­cess to per­son­al­ized ther­a­pies that have helped change the stan­dard of prac­tice for some can­cers.

But a few big things got in the way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.